Skandinaviska Enskilda Banken Ab (Publ) 89bio, Inc. Transaction History

Skandinaviska Enskilda Banken Ab (Publ)

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$6.66 - $16.03 $79,920 - $192,360	-12,000 Reduced 23.35%	39,400 $440,000
Q3 2023 Nov 09, 2023	BUY	$15.06 - $19.41 $373,488 - $481,368	24,800 Added 93.23%	51,400 $794,000
Q2 2023 Aug 07, 2023	BUY	$14.15 - $22.03 $376,390 - $585,998	26,600 New	26,600 $504,000

158

108M

73.6K

1.19M

Ticker ETNB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,484,500
Market Cap $415M
Description
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...

Get notified when there are updates to the investment portfolio of Skandinaviska Enskilda Banken Ab (Publ), based on Form 13F filings with the SEC.

Stay updated on Skandinaviska Enskilda Banken Ab (Publ) with notifications on news.